Eisai to Present New Research on Halaven (Eribulin) at 35th Annual San Antonio
Breast Cancer Symposium
HATFIELD, England, November 28, 2012
HATFIELD, England, November 28, 2012 /PRNewswire/ --
For European Medical Media Only
Eisai will be presenting six abstracts highlighting new study results for
Halaven (eribulin) at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.
The meeting will be held December 4-8, 2012 at the Henry B. Gonzalez
Convention Center in San Antonio, Texas.
These studies highlight Eisai's current and ongoing clinical research efforts
with eribulin, reinforcing the company's commitment to continued research to
patients and their families affected by metastatic breast cancer.
Additionally, Phase III study results of the head-to-head study of eribulin vs
capecitabine will be highlighted as part of a SABCS- sponsored conference to
be held on 7 December, 2012.
"As part of our human health care mission we strive to better understand the
needs of patients and their families to help address unmet medical needs and
increase the benefits that healthcare provides," said Kenichi Nomoto, Ph.D.,
President, Oncology Product Creation Unit at Eisai. "Our continued work to
further understand the clinical profile of eribulin underscores our commitment
to this important mission."
The following Eisai abstracts have been accepted for presentation at this
year's San Antonio Breast Cancer Symposium:
Product Abstract Name
A Phase III, open-label, randomized, multicenter study of
Eribulin eribulin mesylate versus capecitabine in patients with
Session: locally advanced or metastatic breast cancer previously
S6-6 treated with anthracyclines and taxanes
Eribulin Results of a Phase II, multicenter, single-arm study of
Abstract No: eribulin mesylate as first-line therapy for locally
P1-12-02 recurrent or metastatic HER2-negative breast cancer
Eribulin Eribulin mesylate + trastuzumab as first-line therapy for
Abstract No: locally recurrent or metastatic HER2-positive breast
P5-20-04 cancer: results from a Phase II, multicenter, single-arm
Eribulin Adjuvant treatment of early-stage breast cancer with
Abstract No: eribulin mesylate following dose-dense doxorubicin and
P1-13-11 cyclophosphamide: preliminary results from a Phase II,
single-arm feasibility study
Eribulin Post-hoc safety and tolerability assessment in patients
Abstract No. receiving palliative radiation during treatment with
P6-11-14 eribulin mesylate for metastatic breast cancer
N/A Family Members' Burden in Patients with Metastatic and
Abstract No: Early Stage Breast Cancer
P6-09-06 Poster Session
The information discussed in this release is about investigational uses for
eribulin. In Europe, eribulin is indicated for the treatment of patients with
locally advanced or metastatic breast cancer who have progressed after at
least two chemotherapeutic regimens for advanced disease. Prior therapy should
have included an anthracycline and a taxane unless patients were not suitable
for these treatments. ^ It is not intended to convey conclusions of
efficacy and safety.
- ENDS -
Notes to Editors
Halaven ^® (eribulin)
Eribulin is a non-taxane, microtubule dynamics inhibitor indicated for the
treatment of patients with breast cancer who have previously received at least
two chemotherapeutic regimens for metastatic disease and whose prior therapy
should have included an anthracycline and a taxane. Eribulin belongs to a
class of antineoplastic agents, the halichondrins, which are natural products,
isolated from the marine sponge Halichondria okadai. It is believed to work by
inhibiting the growth phase of microtubule dynamics without affecting the
shortening phase and sequesters tubulin into non-productive aggregates.
Halaven is approved in the European Union, USA, Switzerland, Japan, and
Singapore. Halaven has received pricing authorisation and been launched in
Austria, Canada, Denmark, Finland, Germany, Iceland, Italy, Norway, Russia,
South Korea, Sweden, Switzerland, Slovenia, and the UK.
Metastatic Breast Cancer
Metastatic breast cancer is an advanced stage of the disease that occurs when
cancer spreads beyond the breast to other parts of the body. In Europe,
approximately 6% of breast cancers are metastatic at diagnosis with a
five-year survival rate of 21%. ^
Eisai in Oncology
Our commitment to meaningful progress in oncology research, built on
scientific expertise, is supported by a global capability to conduct discovery
and preclinical research, and develop small molecules, therapeutic vaccines,
and biologic and supportive care agents for cancer across multiple
Eisai recently expanded their UK Hatfield commercial, research and
manufacturing facility which now supports the company's growing EMEA business.
Eisai concentrates its R&D activities in three key areas:
*Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight
*Oncology including: anticancer therapies; tumour regression, tumour
suppression, antibodies, etc.
*Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
arthritis, psoriasis, inflammatory bowel disease
With operations in the U.S., Asia, Europe and its domestic home market of
Japan, Eisai employs more than 11,000 people worldwide. In Europe, Eisai
undertakes sales and marketing operations in over 20 markets, including the
United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland,
Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic,
Slovakia, the Netherlands, Belgium, Luxembourg, the Middle East and Russia.
For further information please visit our web site http://www.eisai.com .
1. Halaven (eribulin) Summary of Product Characteristics available from:
http://www.medicines.org.uk/emc/medicine/24382 (Last accessed November 2012)
2. Cardoso, M. and Castiglione F. Locally recurrent or metastatic breast
cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up.
On behalf of the ESMO Guidelines Working Group. Ann Oncol (2009) 20 (suppl 4):
Date of preparation: November 2012
Job code: Halaven-UK0069
Contact: Media Enquiries: Eisai Europe Ltd, Charlotte Andrews / Cressida
Robson, +44-(0)7947-231513, +44-(0)790-831-4155; firstname.lastname@example.org /
email@example.com; Tonic Life Communications, Siobhan Reilly / April
Kenneally, +44-(0)207-798-9999 / +44-(0)784-047-3199, +44-(0)207-798-9263 /
+44-(0)788-561-4274, firstname.lastname@example.org / email@example.com
Press spacebar to pause and continue. Press esc to stop.